^
Association details:
| Biomarker: | DKK3 overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
High DKK3 expression related to immunosuppression was associated with poor prognosis in glioblastoma: machine learning approach
Published date:
05/23/2022
Excerpt:
Through in vitro drug screening, we identified navitoclax as an agent with potent activity against GBM cell lines with high DKK3 expression....Navitoclax (ABT-263) reduced the growth of cancer cell lines with high DKK3 expression (r = −0.338, p = 0.018 [Pearson’s correlation] and 0.023 [Student’s t test]) (Fig. 4D).
DOI:
10.1007/s00262-022-03222-4
